Skip to main content
. 2008 May 21;28(21):5422–5432. doi: 10.1523/JNEUROSCI.0955-08.2008

Table 1.

Neurologic features in Tsc1null-neuron mice according to age and treatment

Genotype class Treatment Age n Weight (g) Weight SD Clasp Tremor Kyphosis Tail
% Tsc1c SynICre+
    46% Mutant None P30 16 9.87 1.59 0.63 3.28 0.81 2.73
    65% Mutant Rapamycin P30 17 10.27 2.05 0 0.12 0 0.88
    88% Mutant RAD001 P30 17 11.14 1.14 0 0.26 0 1.24
    92% Mutant Rapamycin P60 12 14.39 2.68 0 0.42 0.17 0.83
    86% Mutant rap-P30 P60 9 16.13 2.48 0 1.94 0.67 1.14
    71% Mutant Rapamycin P100 14 18.13 1.84 0 0.64 0.14 0.79
    82% Mutant RAD001 P100 11 19.59 2.30 0.09 1.00 0.27 0.73
% Tsc1c+ SynICre+
    89% Control None P30 10 20.32 2.85 0 0.35 0 0.30
    100% Control Rapamycin P30 4 11.50 0.27 0 0.25 0 0
    86% Control RAD001 P30 7 12.66 2.33 0.14 0.14 0 0.14
    57% Control Rapamycin P60 7 18.39 2.31 0 0.36 0 0.57
    75% Control Rapamycin P100 9 19.56 2.25 0 0.39 0 0.56
    78% Control RAD001 P100 9 20.76 2.91 0 0.22 0.22 0.44

Mutant refers to Tsc1null-neuron mice. Mutants had genotypes Tsc1c SynICre+ or Tsc1cc SynICre+; % Tsc1c SynICre+ is shown in the first column for mutants. Controls had genotypes Tsc1c+ SynICre+, Tsc1c+ SynICre, Tsc1cc SynICre, Tsc1c SynICre; % Tsc1c+ SynICre+ is shown in the first column for controls. All treatments were 6 mg/kg intraperitoneally every other day, beginning at P7–P9. Rapamycin on/off mice were treated until P30, and then drug was discontinued; all others were treated continuously. Average values for weight in grams and standard deviation (SD) are shown. Average values for clasping, tremor, kyphosis, and tail position scores are shown and were assessed as described in Materials and Methods. Tremor and tail position were scored on 0–5 and 0–3 scales, respectively. Clasping and kyphosis were assessed on a binary 0 (absent) or 1 (present) scale. Note that all neurologic scores as well as weight were significantly different (p < 0.003 for each) between untreated mutant and control mice at P30. All neurologic scores, but not weight, were also significantly different (p < 0.003 for each) between P30 mutant and rapamcyin- or RAD001-treated P30 mice. There was no significant difference between weight or any neurologic score between rapamycin- and RAD001- treated mice at either P30 or P100. There was a significant difference between rapamycin-treated P60 and rapamycin-treated 22 d only P60 (rap on/off) mice in both tremor (p = 0.0003) and kyphosis (p = 0.02).